• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2022 Fiscal Year Final Research Report

Investigation of the mechanism of chemotherapy-induced peripheral neuropathy and development of new therapeutic strategy

Research Project

  • PDF
Project/Area Number 20K07168
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 47060:Clinical pharmacy-related
Research InstitutionKindai University

Principal Investigator

TSUBAKI Masanobu  近畿大学, 薬学部, 准教授 (30434856)

Project Period (FY) 2020-04-01 – 2023-03-31
Keywords抗がん剤誘発末梢神経障害 / 分子標的薬
Outline of Final Research Achievements

We investigated the mechanisms of oxaliplatin, paclitaxel, and bortezomib-induced neuropathy, and found that activation of the ERK pathway in the lumbar region is involved. We also found that molecularly targeted drugs inhibition of the MEK/ERK pathway prevented oxaliplatin-, paclitaxel-, and bortezomib-induced neuropathy via inhibition of the ERK pathway. These results may contribute to the treatment of oxaliplatin-, paclitaxel-, and bortezomib-induced neuropathy in clinical practice. The results of this study are summarized in the main publications section.

Free Research Field

薬物治療学

Academic Significance and Societal Importance of the Research Achievements

現在、臨床においてオキサリプラチン、パクリタキセル及びボルテゾミブ誘発末梢神経障害の予防、治療法は確立されていない。さらに、これら抗がん剤による末梢神経障害は患者のQOLを低下させるだけではなく、投与の継続も不可能となるため患者は著しく不利益をこうむる。本成果においてオキサリプラチン、パクリタキセル及びボルテゾミブ誘発性末梢神経障害にMEK/ERK経路の活性化が関与することを明らかにし、その抑制薬により完全に末梢神経障害を抑制できることを見出した。これらの結果により、オキサリプラチン、パクリタキセル及びボルテゾミブの継続投与が可能となり、患者の予後、QOLの改善に貢献できると考えている。

URL: 

Published: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi